Beijing Konruns Pharmaceutical (603590.SH): KC1036 combined with PD-1 antibody and platinum-containing chemotherapy for first-line treatment of advanced recurrent or metastatic esophageal squamous cell carcinoma approved for clinical trial.

Beijing Konruns Pharmaceutical (603590.SH) announced that they have recently received a clinical trial notification for the chemical class 1 innovative drug KC1036 tablets approved and issued by the National Medical Products Administration. The trial is for the use of KC1036 in combination with PD-1 antibodies and platinum-based chemotherapy as a first-line treatment for advanced recurrent or metastatic esophageal squamous cell carcinoma, and will be conducted in the near future. KC1036 is a chemical class 1 innovative drug developed independently by the company, and the company holds the global intellectual property rights for this product. KC1036 achieves anti-tumor activity by inhibiting multiple targets such as VEGFR2 and AXL. It has strong VEGFR vascular targeting capability to inhibit tumor cell growth, and by inhibiting AXL, it can improve the host's anti-tumor immune response to prevent tumor immune evasion. Currently, clinical studies for KC1036 are being conducted for multiple indications including digestive system tumors, thymus tumors, and childhood Ewing's sarcoma. As of now, over 300 subjects have been enrolled in KC1036 clinical studies, with promising anti-tumor activity, good safety, and tolerability demonstrated in the results of these studies.